This HTML5 document contains 106 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n32http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/pharmgkb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/kegg-compound/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/pdb/
n15http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/pubchem-substance/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00987/identifier/chemspider/
n20http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00987
rdf:type
n3:Drug
n3:description
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
n3:dosage
n9:271B4A0D-363D-11E5-9242-09173F13E4C5 n9:271B4A0E-363D-11E5-9242-09173F13E4C5 n9:271B4A0F-363D-11E5-9242-09173F13E4C5 n9:271B4A10-363D-11E5-9242-09173F13E4C5 n9:271B4A11-363D-11E5-9242-09173F13E4C5 n9:271B4A05-363D-11E5-9242-09173F13E4C5 n9:271B4A06-363D-11E5-9242-09173F13E4C5 n9:271B4A07-363D-11E5-9242-09173F13E4C5 n9:271B4A08-363D-11E5-9242-09173F13E4C5 n9:271B4A09-363D-11E5-9242-09173F13E4C5 n9:271B4A0A-363D-11E5-9242-09173F13E4C5 n9:271B4A0B-363D-11E5-9242-09173F13E4C5 n9:271B4A0C-363D-11E5-9242-09173F13E4C5 n9:271B4A04-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
10 minutes
n3:indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
n3:manufacturer
n16:271B4A00-363D-11E5-9242-09173F13E4C5 n16:271B49FE-363D-11E5-9242-09173F13E4C5 n16:271B49FF-363D-11E5-9242-09173F13E4C5 n16:271B49FC-363D-11E5-9242-09173F13E4C5 n16:271B49FD-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00987 n17:DB00987
dcterms:title
Cytarabine
adms:identifier
n6:6253 n7:46505879 n10:PA449177 n11:Cytarabine n25:57665-331-01 n26:AR3 n27:C02961 n28:D00168 n29:DB00987 n30:28680 n31:6017
n3:mechanismOfAction
Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.
n3:packager
n16:271B49F4-363D-11E5-9242-09173F13E4C5 n16:271B49FA-363D-11E5-9242-09173F13E4C5 n16:271B49FB-363D-11E5-9242-09173F13E4C5 n16:271B49F7-363D-11E5-9242-09173F13E4C5 n16:271B49F8-363D-11E5-9242-09173F13E4C5 n16:271B49F5-363D-11E5-9242-09173F13E4C5 n16:271B49F6-363D-11E5-9242-09173F13E4C5 n16:271B49F9-363D-11E5-9242-09173F13E4C5
n3:patent
n4:5455044 n4:5723147
n3:routeOfElimination
The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U.
n3:synonym
Cytarabinum Citarabina Ara-C Arabinofuranosyl Cytidine Cytosine-beta-D-arabinofuranoside 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone Cytosine-1-beta-D-arabinofuranoside 1-beta-D-Arabinofuranosylcytosine Cytarabine cytosine-β-D-arabinofuranoside Cytosine arabinoside
n3:toxicity
Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.
n18:hasAHFSCode
n19:10-00-00
n3:proteinBinding
13%
n3:synthesisReference
Michael Kluge, Herbert Schott, "Cytarabine derivatives, the preparation and use thereof." U.S. Patent US5641758, issued August, 1992.
n22:hasConcept
n23:M0005564
foaf:page
n13:cytarabine.html n32:cytarabine.htm
n3:IUPAC-Name
n8:271B4A16-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B4A1C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B4A1B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B4A18-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B4A19-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B4A1A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B4A14-363D-11E5-9242-09173F13E4C5 n8:271B4A2C-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B4A12-363D-11E5-9242-09173F13E4C5 n8:271B4A15-363D-11E5-9242-09173F13E4C5 n8:271B4A2E-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B4A13-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n20:L01BC01
n3:H-Bond-Acceptor-Count
n8:271B4A22-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B4A23-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B4A1D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B4A1E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B4A20-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B4A1F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B4A21-363D-11E5-9242-09173F13E4C5
n3:absorption
Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
147-94-4
n3:category
n3:containedIn
n24:271B4A01-363D-11E5-9242-09173F13E4C5 n24:271B4A02-363D-11E5-9242-09173F13E4C5 n24:271B4A03-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B4A28-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B4A2A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B4A2B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B4A2D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B4A27-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B4A26-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B4A29-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B4A17-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B4A24-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B4A25-363D-11E5-9242-09173F13E4C5